<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04570527</url>
  </required_header>
  <id_info>
    <org_study_id>OB-CAD</org_study_id>
    <nct_id>NCT04570527</nct_id>
  </id_info>
  <brief_title>Optimized Cardioprotection Therapy in Obese Subjects With CAD</brief_title>
  <official_title>Effects and Mechanism of Adipokines Cardiac Protection in Obese Patients With Coronary Artery Disease (CAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and mechanism of Adipokines Cardiac&#xD;
      Protection in Obese Patients With coronary artery disease (CAD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adipokines (or adipocytokines) can be defined as a group of more than 600 bioactive molecules&#xD;
      made from adipose tissue that acts as paracrine and endocrine hormones. Adipokines are&#xD;
      involved in maintaining varieties of processes such as, appetite and satiety, energy&#xD;
      expenditure activity, endothelial function, blood pressure, hemostasis, adipogenesis, insulin&#xD;
      sensitivity, energy metabolism in insulin-sensitive tissues, fat distribution and insulin&#xD;
      secretion in pancreatic Î²-cells. Adipokines may contribute to reduce scar formation and&#xD;
      improve cardiac function in coronary artery disease (CAD). Reperfusion therapy such as&#xD;
      percutaneous coronary intervention (PCI) should be administered to all eligible patients with&#xD;
      CAD symptom. However, our previous work showed that obese patients may benefit more from PCI.&#xD;
      Thus, the aim of the present study was to investigate the efficacy and mechanism of&#xD;
      adipokines cardiac protection for obese and non-obese patients with coronary artery disease&#xD;
      (CAD).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patient death during the follow up period</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of target vessel revascularization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina class according to the canadian cardiovascular society (CCS) classification</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores on the Seattle angina questionnaire</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>six-min walk distance (6MWD)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))</condition>
  <condition>Obesity</condition>
  <condition>Adiposis; Heart</condition>
  <arm_group>
    <arm_group_label>Obesity</arm_group_label>
    <description>BMI&gt;=25</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Obesity</arm_group_label>
    <description>BMI&lt;25</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCI</intervention_name>
    <description>percutaneous coronary intervention</description>
    <arm_group_label>Non-Obesity</arm_group_label>
    <arm_group_label>Obesity</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of CAD were enrolled in this study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        coronary artery disease according to the WHO definition With or without percutaneous&#xD;
        coronary intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        previous Coronary artery bypass grafting (CABG) cardiomyopathy atrial fibrillation or&#xD;
        flutter previous heart surgery severe valvular heart disease disease of the hematopoietic&#xD;
        system NYHA functional class IV heart failure at baseline severe renal, lung and liver&#xD;
        disease cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongdong Sun, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dongdong Sun, MD, PhD</last_name>
    <phone>86 29 84775183</phone>
    <email>wintersun3@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wanrong Man, MD</last_name>
    <phone>86 29 84775183</phone>
    <email>Manwanrong@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xijing hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongdong Sun, M.D.,Ph.D</last_name>
      <phone>86 18691569930</phone>
      <email>wintersun3@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Wanrong Man, M.D.</last_name>
      <phone>86 15352312311</phone>
      <email>manwanrong@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dongdong Sun, M.D.,Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>September 25, 2020</last_update_submitted>
  <last_update_submitted_qc>September 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>sunddong</investigator_full_name>
    <investigator_title>Cardiology department</investigator_title>
  </responsible_party>
  <keyword>Coronary artery disease</keyword>
  <keyword>Adipokines</keyword>
  <keyword>Obesity</keyword>
  <keyword>Diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

